• Expert Opin Pharmacother · Aug 2008

    Review

    Azacitidine and the beginnings of therapeutic epigenetic modulation.

    • Kristen O'Dwyer and Peter Maslak.
    • Memorial Sloan-Kettering Cancer Center, Leukemia Service, Department of Medicine, New York, 10021, USA.
    • Expert Opin Pharmacother. 2008 Aug 1; 9 (11): 1981-6.

    BackgroundAlthough originally developed as a cytarabine analog more than 40 years ago, azacitidine has been the subject of renewed interest in the era of cancer epigenetics.ObjectiveWhat is the history of the clinical development of azacitidine and how has it been applied successfully to the treatment of myelodysplastic syndromes (MDS)?MethodsWe review the evolution of the use of azacitidine for the therapy of human disease and review the major studies that have laid the groundwork for its current clinical indication.ConclusionThe use of azacitidine has changed the approach to the treatment of MDS and has resulted in improved outcomes for patients.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…